- Home
- SNN vs VTRS Comparison
SNN vs VTRS Comparison
Compare SNN & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNN
- VTRS
- Stock Information
- Founded
- SNN 1856
- VTRS 1961
- Country
- SNN United Kingdom
- VTRS United States
- Employees
- SNN N/A
- VTRS N/A
- Industry
- SNN Industrial Specialties
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- SNN Health Care
- VTRS Health Care
- Exchange
- SNN Nasdaq
- VTRS Nasdaq
- Market Cap
- SNN 12.7B
- VTRS 10.2B
- IPO Year
- SNN 1999
- VTRS N/A
- Fundamental
- Price
- SNN $28.83
- VTRS $8.83
- Analyst Decision
- SNN Hold
- VTRS Hold
- Analyst Count
- SNN 3
- VTRS 5
- Target Price
- SNN $27.50
- VTRS $10.40
- AVG Volume (30 Days)
- SNN 801.1K
- VTRS 16.9M
- Earning Date
- SNN 07-31-2025
- VTRS 08-07-2025
- Dividend Yield
- SNN 2.60%
- VTRS 5.41%
- EPS Growth
- SNN 56.15
- VTRS N/A
- EPS
- SNN 0.47
- VTRS N/A
- Revenue
- SNN $5,810,000,000.00
- VTRS $14,330,200,000.00
- Revenue This Year
- SNN $6.87
- VTRS N/A
- Revenue Next Year
- SNN $5.19
- VTRS $1.89
- P/E Ratio
- SNN $30.88
- VTRS N/A
- Revenue Growth
- SNN 4.70
- VTRS N/A
- 52 Week Low
- SNN $23.69
- VTRS $6.85
- 52 Week High
- SNN $31.72
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- SNN 49.61
- VTRS 51.17
- Support Level
- SNN $28.40
- VTRS $8.66
- Resistance Level
- SNN $30.38
- VTRS $9.19
- Average True Range (ATR)
- SNN 0.36
- VTRS 0.23
- MACD
- SNN -0.17
- VTRS -0.01
- Stochastic Oscillator
- SNN 30.00
- VTRS 48.11
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.